<unk> , sold under the brand name Carvykti, is a medication used to treat multiple myeloma. The most common adverse reactions include pyrexia, cytokine release syndrome, hypogammaglobulinemia, musculoskeletal pain, fatigue, infections, diarrhea, nausea, encephalopathy, headache, coagulopathy, constipation, and vomiting.<unk>  is a B-cell maturation antigen (BCMA)-directed genetically modified autologous chimeric antigen receptor (CAR) T-cell therapy. Each dose is customized using the recipient's own T-cells, which are collected and genetically modified, and infused back into the recipient.<unk>  was approved for medical use in the United States in February 2022.
Ciltacabtagene autoleucel
Brexucabtagene autoleucel
Lisocabtagene maraleucel
Idecabtagene vicleucel
Ibrexafungerp
Levomilnacipran
Nicogel
Brodifacoum